Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome

Introduction: The aim of this study was to measure electroneurographic (ENG) parameters of the median and ulnar nerve in patients with metabolic syndrome and to determine whether the large imbalance in glycemic control came to neuropathic changes to the template.Methods: The study included 100 patients with metabolic syndrome diagnosed according to the criteria of the National Cholesterol Education Program - Adult Treatment Panel III (NCEP-ATP III). The patients were divided into two groups. Group I – patients with normal glycemic control and Group II - patients with diabetes mellitus for up to five years. We measured sensory conductive velocity (SCV), the amplitude of sensory nerve action potential (SNAP), motor conductive velocity (MCV), terminal motor latency (TML) and compose muscle action potential after distal stimulation (CMAP-I) and after proximal stimulation (CMAP-II) for the ulnar and median nerve.Results: Sensory and motor parameters in Group II were amended to neuropathic pattern compared to Group I. There were significant differences in: SNAP amplitude for all tested nerves, SCV values for both left and right median and ulnar nerve; MCV and TML for left median nerve; MCV, TML and CMAP-I for right median nerve area; MCV and TML for left ulnar nerve; MCV, CMAP-I and CMAP-II for right ulnar nerve area.Conclusion: Patients with metabolic syndrome and diabetes mellitus duration of five years have the significant changes in sensory and motor peripheral nerves. Neuropathic changes are possible in patients with metabolic syndrome and normal glycemic control.

Download Full-text

Investigate the level of IL-8 in patients with diabetes mellitus and its relation with lipid profile and the incidence of atherosclerosis

European Journal of Chemistry ◽

10.5155/eurjchem.5.3.529-531.1084 ◽

2014 ◽

Vol 5 (3) ◽

pp. 529-531

Author(s):

Ammal Esmaeel Ibrahim

Keyword(s):

Diabetes Mellitus ◽

Lipid Profile ◽

Patients With Diabetes

Download Full-text

Influence of glucose control on the main parameters of serum lipid profile and platelet membranes in patients with metabolic syndrome and type 2 diabetes mellitus

Atherosclerosis Supplements ◽

10.1016/s1567-5688(02)80453-6 ◽

2002 ◽

Vol 3 (2) ◽

pp. 163 ◽

Cited By ~ 1

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Metabolic Syndrome ◽

Type 2 Diabetes Mellitus ◽

Lipid Profile ◽

Glucose Control ◽

Serum Lipid ◽

Serum Lipid Profile ◽

Platelet Membranes

Download Full-text

Prevalence of the metabolic syndrome in patients with diabetes mellitus

Irish Journal of Medical Science (1971 -) ◽

10.1007/s11845-009-0302-z ◽

2009 ◽

Vol 178 (3) ◽

pp. 309-313 ◽

Cited By ~ 16

Author(s):

F. AlSaraj ◽

J. H. McDermott ◽

T. Cawood ◽

S. McAteer ◽

M. Ali ◽

...

Keyword(s):

Diabetes Mellitus ◽

Metabolic Syndrome ◽

The Metabolic Syndrome ◽

Patients With Diabetes

Download Full-text

459 Evaluation of LDL-C reductions by siRNA treatment with inclisiran in patients with diabetes mellitus, metabolic syndrome or neither

European Heart Journal Supplements ◽

10.1093/eurheartj/suab136.001 ◽

2021 ◽

Vol 23 (Supplement_G) ◽

Author(s):

R. Scott Wright ◽

David Kallend ◽

Kausik K Ray ◽

Lawrence Leiter ◽

Wolfgang Koenig ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Cardiovascular Disease ◽

Metabolic Syndrome ◽

Controlled Trial ◽

Atherosclerotic Cardiovascular Disease ◽

Double Blind ◽

Sirna Treatment ◽

Patients With Diabetes

Abstract Aims Patients with diabetes (DM) and metabolic syndrome (MS) have elevated risks for atherosclerotic cardiovascular disease (ASCVD). Aggressive LDL-C lowering reduces risks. Inclisiran, a new siRNA, lowers LDL-C and was evaluated in patients with Type 2 diabetes (DM), metabolic syndrome (MS) without DM or neither (N) in the ORION-10 trial. Methods ORION-10 was a double-blind, randomized, placebo controlled trial evaluating inclisiran in 1561 patients with ASCVD on maximally tolerated therapy for lowering LDL-C. 781 inclisiran (INC) participants and 780 placebo (P) patients received 1.5 mL SQ tx at Days 1, 90, then every 6 months until Day 540. We evaluated the time adjusted change in LDL-C from baseline after Days 90–540 in DM (n = 702), MS (n = 455) and N participants (n = 404). Results There were no differences in baseline demographics and background therapies between INC and P. Statins were utilized in 89.8% INC and 88.7% of P. High intensity statins were utilized in 67.2% of INC and 68.8% of P; ezetimibe in 10.2% of NC and 9.5% of P participants. INC reduced LDL-C by − 54.4% (−58.3, −50.6 95% CI) in DM, (P < 0.001), −58.6% (−62.3, −54.8), P < 0.001 in-MS and −56.0% (−60.2, −51.7), in N subjects P < 0.001 (see Figure). Conclusions Inclisiran potently and durably reduces LDL-C across patients with DM, MS and those with neither, demonstrating potent efficacy and durability across glycaemic categories. Inclisiran may also represent a potent LDL-C lowering treatment for those with DM and MS.

Download Full-text

Impact of Crocus sativus L. on Metabolic Profile in Patients with Diabetes Mellitus or Metabolic Syndrome: A Systematic Review

Nutrients ◽

10.3390/nu12051424 ◽

2020 ◽

Vol 12 (5) ◽

pp. 1424 ◽

Cited By ~ 2

Author(s):

Parthena Giannoulaki ◽

Evangelia Kotzakioulafi ◽

Michail Chourdakis ◽

Apostolos Hatzitolios ◽

Triantafyllos Didangelos

Keyword(s):

Diabetes Mellitus ◽

Systematic Review ◽

Metabolic Syndrome ◽

Metabolic Profile ◽

Density Lipoprotein ◽

Crocus Sativus ◽

Favorable Effect ◽

Patients With Diabetes ◽

Artery Disease ◽

Crocus Sativus L

Background: Experimental studies demonstrated a positive effect of administration of Crocus sativus L. (saffron) and its bioactive ingredients on metabolic profile through their antioxidant capacity. Purpose: To determine if the use of saffron in humans is beneficial to patients with diabetes mellitus (DM) or metabolic syndrome (MS). Methods: This systematic review includes 14 randomized control trials that investigated the impact of saffron administration and its bioactive ingredient crocin on the metabolic profile of patients with DM, MS, prediabetes, and coronary artery disease. We documented the following clinical outcomes: fasting blood glucose (FBG), glycated haemoglobin (HbA1c), total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, systolic, and diastolic blood pressure. Results: Eight studies examined the efficacy of saffron in patients with DM, four with the metabolic syndrome, one with prediabetes and one with coronary artery disease. A favorable effect on FBG was observed. The results regarding blood lipids and blood pressure were inconclusive in the current review. Conclusions: According to the available limited evidence, saffron may have a favorable effect on FBG. Many of the studies in the reviewed literature are of poor quality, and more research is needed in this direction to confirm and establish the above findings.

Download Full-text